Literature DB >> 26000562

Management and prognosis of atrial fibrillation in the diabetic patient.

Jannik Langtved Pallisgaard1, Tommi Bo Lindhardt, Jonas Bjerring Olesen, Morten Lock Hansen, Nicholas Carlson, Gunnar Hilmar Gislason.   

Abstract

The global burden of atrial fibrillation and diabetes mellitus (diabetes) is considerable, and prevalence rates are increasing. Diabetes is associated with an increased risk of developing atrial fibrillation; however, diabetes also influences the management and prognosis of atrial fibrillation. In the following article, the authors describe the association between diabetes and atrial fibrillation; specifically, the significance of diabetes on the risk of atrial fibrillation, ischemic stroke and bleeding complications associated with anticoagulation. In addition, the authors evaluate the risks and outcomes of heart failure and the success rates of both ablation and cardioversion in atrial fibrillation patients with diabetes. Finally, this article describes the association of HbA1c levels with the management and prognosis of atrial fibrillation patients.

Entities:  

Keywords:  HbA1c; ablation; atrial fibrillation; bleeding; cardioversion; diabetes mellitus; heart failure; novel oral anticoagulants; stroke

Mesh:

Substances:

Year:  2015        PMID: 26000562     DOI: 10.1586/14779072.2015.1043892

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  8 in total

1.  Effects of acute hyperglycaemia on cardiovascular homeostasis: does a spoonful of sugar make the flow-mediated dilatation go down?

Authors:  John David Horowitz; Cher-Rin Chong; Doan T Ngo; Aaron Leonid Sverdlov
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

Review 2.  Catheter ablation in atrial fibrillation: is there a mortality benefit in patients with diabetes and heart failure?

Authors:  M Matta; A Saglietto; P De Salvo; A Bissolino; A Ballatore; M Anselmino
Journal:  Herz       Date:  2019-05       Impact factor: 1.443

3.  Thiazolidinediones and Risk of Atrial Fibrillation Among Patients with Diabetes and Coronary Disease.

Authors:  Jannik Langtved Pallisgaard; Maria Mori Brooks; Bernard R Chaitman; Derek B Boothroyd; Marco Perez; Mark A Hlatky
Journal:  Am J Med       Date:  2018-03-23       Impact factor: 4.965

Review 4.  Evaluating the benefits of home-based management of atrial fibrillation: current perspectives.

Authors:  Azfar B Sheikh; Jamie R Felzer; Abdullah Bin Munir; Daniel P Morin; Carl J Lavie
Journal:  Pragmat Obs Res       Date:  2016-10-13

5.  Patients with atrial fibrillation and permanent pacemaker: Temporal changes in patient characteristics and pharmacotherapy.

Authors:  Frederik Dalgaard; Martin H Ruwald; Tommi Bo Lindhardt; Gunnar H Gislason; Christian Torp-Pedersen; Jannik L Pallisgaard
Journal:  PLoS One       Date:  2018-03-28       Impact factor: 3.240

6.  Global research productions pertaining to atrial fibrillation from 2004 to 2018: A bibliometric analysis.

Authors:  Shuqing Shi; Jingjing Shi; Shuai Shi; Qiulei Jia; Guozhen Yuan; Yi Wei; Dandan Wang; Yuanhui Hu
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

Review 7.  Glycemic control and atrial fibrillation: an intricate relationship, yet under investigation.

Authors:  Andreas S Papazoglou; Anastasios Kartas; Dimitrios V Moysidis; Christos Tsagkaris; Stavros P Papadakos; Alexandra Bekiaridou; Athanasios Samaras; Efstratios Karagiannidis; Marios Papadakis; George Giannakoulas
Journal:  Cardiovasc Diabetol       Date:  2022-03-14       Impact factor: 9.951

8.  Risk Factors for Failure of Direct Current Cardioversion in Patients with Type 2 Diabetes Mellitus and Atrial Fibrillation.

Authors:  Handrean Soran; Moulinath Banerjee; Jamal B Mohamad; Safwaan Adam; Jan Hoong Ho; Shakawan M Ismaeel; Shaishav Dhage; Akheel A Syed; Ibrahem M A Abdulla; Naveed Younis; Rayaz A Malik
Journal:  Biomed Res Int       Date:  2018-03-12       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.